New drug shows weight loss promise
Digest more
Drugmakers are targeting muscle preservation and fat loss as they build the next generation of weight-loss medications.
Viking Therapeutics tested various doses of its leading anti-obesity candidate, VK2735, administered subcutaneously every other week or monthly (VK2735 also mimics the action of the GIP hormone). The results were impressive.
Consumer guide finds no controlled human trial demonstrating that a baking soda water shot causes weight loss; current
Weekly survodutide 3.6 mg/6.0 mg achieved up to 13.1% mean weight loss at week 76 versus 3.1% with placebo, meeting co-primary endpoints under treatment-regimen and efficacy estimands. A ≥5% weight reduction occurred in up to 79.
Dr. Tommy Wood warns GLP-1 drugs like Ozempic and Wegovy can shrink brain tissue when caloric restriction cuts off vital energy the brain needs.
No. 52 / 2026 Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes In the SYNCHRONIZE-2 trial,
Lilly said it plans to start Phase 3 trials on the combo regimen adding its amylin drug eloralintide to tirzepatide at the end of the year.